Sirius Medical is excited to announce a major milestone in our journey to revolutionize cancer care with our groundbreaking localization technology. We have successfully raised $10,000,000 in our recent funding round, a pivotal investment that will accelerate our mission to empower surgeons and enhance patient outcomes. As a spin-off of the esteemed Netherlands Cancer Institute, Sirius Medical was born from a deep understanding of the challenges faced in breast cancer surgeries. Our pioneering work led to the development of the first magnetic seed localization technique, which has since evolved into our flagship solution—the Sirius Pintuition System.
The new capital infusion will help us further refine and expand the capabilities of the Sirius Pintuition platform, the only wire-free localization technology offering seamless navigational guidance. With state-of-the-art features such as GPSDetect™ software and the unique TargetLOC™ feature, Pintuition provides real-time, audio and visual directional feedback to ensure unmatched precision in tumor detection. This funding will empower us to drive the next phase of clinical research, enhance manufacturing capabilities, and extend our market presence beyond the current 200 centers across the United States and western Europe.
Our commitment to delivering unsurpassed yet affordable solutions remains unwavering as we continue to innovate and simplify the process of tumor localization. By harnessing these funds, we aspire to further improve the surgical experience for physicians and ensure that more cancer patients benefit from efficient and precise tumor removal. At Sirius Medical, we firmly believe that when it comes to cancer surgery, precision is paramount—don’t settle for localization, navigate with Pintuition.
